GlobeNewswire Inc.··NaOvid Therapeutics Raises $60M in PIPE Funding to Accelerate Rare Disease Pipeline
Ovid Therapeutics secures $60M in PIPE funding led by Point72 to advance OV329 development in rare neurological diseases including tuberous sclerosis complex and infantile spasms.
OVIDPIPE financingOV329